Ocera Therapeutics, Inc.

Ocera Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions, with a strong emphasis on oncology and autoimmune diseases, aiming to improve patient outcomes through innovative treatment solutions. Founded in San Diego, US, Ocera Therapeutics, Inc. specializes in biopharmaceutical development.

The company underwent a merger in April 2013 with a subsidiary of Tranzyme, transforming it into a public entity. The latest funding round, a VENTURE DEBT of USD 20. 00 mn, was completed on March 24, 2013. Notably, the company has raised a total of USD 28.

00 mn through multiple funding rounds with investors including Oxford Financial Corporation and Silicon Valley Bank. Ocera Therapeutics focuses on developing innovative biopharmaceutical solutions aimed at addressing critical healthcare needs. The company's core product offerings include a range of therapeutics targeting various chronic conditions, particularly in the fields of oncology and autoimmune diseases. These products are designed to enhance patient outcomes through mechanisms that involve modulation of the immune response or targeted cell therapy.

Ocera Therapeutics primarily serves healthcare institutions, including hospitals and specialty clinics, catering to a diverse client base that includes healthcare providers, patients, and potentially research institutions involved in clinical trials. The geographical markets for these products extend to North America and select regions in Europe, where the company aims to meet the increasing demand for advanced therapeutic solutions. Ocera Therapeutics generates revenue through a structured model that includes direct sales to healthcare providers and partnerships with pharmaceutical distributors. In the most recent year, the company's revenue amounted to USD 609,000, with an EBITDA of USD -25,641,000.

The company has established a transaction framework supporting both B2B and direct-to-consumer sales, enabling it to reach a wide audience. Revenue is derived from the sale of its flagship therapeutics, with clients typically engaging in bulk purchasing agreements or subscription models for ongoing supply. Specific pricing plans are tailored to the nature of the products and services, reflecting the value and innovation offered by Ocera Therapeutics' proprietary therapies. This approach not only solidifies client relationships but also enhances the company's market presence in the biopharmaceutical landscape.

Ocera Therapeutics has plans to develop new products targeting oncology and autoimmune diseases, with specific launch timelines yet to be announced. The company is also considering expansion into new geographic markets, including additional regions in Europe by the end of 2015. The recent VENTURE DEBT funding of USD 20. 00 mn will be utilized to support these initiatives, enhancing product development and facilitating market entry efforts.